Satellite Symposia

Satellite symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information.  

Thursday, May 3

Satellite Symposium - Pfizer Oncology (18:30 - 20:00)

Management of Patients with ER + HER2 - Metastatic Breast Cancer

Xinni Song, Assistant Professor of Medicine, University of Ottawa, Division of Medical Oncology, Ottawa, ON

Learning Objectives:

  • Treating ER+ HER2- MBC patients –a review of the treatment guidelines;
  • The role of the multidisciplinary healthcare team in the management of patients with ER+ MBC; and
  • Clinical use  of the CDK 4/6 inhibitors– case based discussion on dose, monitoring requirement and side effect management.

Friday, May 4

Satellite Symposium - Apobiologix (07:00 - 08:30)

The Science Behind Biosimilars

The value that biosimilars bring to the healthcare system is their potential to provide significant cost savings thereby contributing to sustainability and accessibility. Realizing this potential is, in large part, dependent upon how well biosimilars are understood by healthcare providers, patients and payers. Significant advances in technology, analytics and manufacturing of biologic medicines has kept pace over the decades. This symposium will take a deeper dive into the science behind biosimilars focusing on how these advances have been applied to the development of biosimilar medicines.

Satellite Symposium - Amgen (08:45-10:15)

Optimizing the Opportunity: What the Pharmacist Needs to Know About Therapeutic Biosimilars in Oncology

The introduction of therapeutic biosimilars represents another step forward in providing more lifesaving treatment options to patients with cancer.
Oncology healthcare professionals will soon be faced with new decisions as they adopt therapeutic biosimilars into the solid tumour treatment armamentarium.
Learning Objectives:
  • Compare and contrast the development process for generic drugs and oncology therapeutic biosimilars;
  • Examine the scientific evidence and regulatory requirements for marketing authorization of oncology therapeutic biosimilars; and
  • Explore clinical considerations and practical issues associated with day-to-day choices related to oncology therapeutic biosimilars.

Satellite Symposium - AstraZeneca (10:30 - 12:00)

Practice Update: Locally Advanced Non-Small Cell Lung Cancer

This is a multidisciplinary education program for healthcare professionals involved in care of patients with locally advanced non-small cell lung cancer (NSCLC).

Learning Objectives:
  • Recognize unmet needs in locally advanced NSCLC;
  • Support evidence-based treatment decisions; and
  • Create awareness of future developments that may influence patient care.

Satellite Symposium - Astellas (12:15 - 13:45)

Energize the fight against cancer-related fatigue: Holistic management and the patient perspective

Learning Objectives:
  1. Describe the multi-factorial causes of cancer-related fatigue (CRF) and the importance of a multi-disciplinary approach to fatigue management;
  2. Recognize the role of pharmacists and the importance of collaboration with other HCPs to optimize patient CRF management; and
  3. Discover the patient perspective on CRF and consider how to better prepare patients and caregivers to effectively manage CRF.

Satellite Symposium - Ipsen (14:00 - 15:30)

Optimizing the Management of Patients with Rare Cancers: The Neuroendocrine Tumors (NET’s) Patient Journey

Tim Asmis, BSc, MD, FRCP(C), Medical Oncologist,Ottawa Hospital Cancer Centre
Alia Thawer, BSc, BScPharm, PharmD, RPh, Pharmacist, Sunnybrook Health Sciences Centre
Sherry O'Grady Fox, CNETS Support Group Leader, Ottawa

Neuroendocrine tumours or NETs is a group of uncommon tumours that develops in the cells of the neuroendocrine system throughout the body.  Patients with NETs do not have a clear path of care in their cancer journey, therefore the multidisciplinary team approach is important to providing support and building patient and family resilience.

Learning Objectives:

  • Gain a deeper understanding of the NETs journey from the patient perspective;
  • Review treatment options for patients with NETs and the role of the multi-disciplinary team;
  • Assess practical considerations for the role of SSAs in the management of NETS; and
  • Articulate the role of the pharmacist in supporting patients with rare cancers.

Satellite Symposium - Hoffmann - La Roche (15:45 - 17:15)

Formulations Advances in Oncology

Scott Edwards, Pharm.D., MSc (Oncology), Assistant Professor, Memorial University St. John’s, NL 
Douglas Stewart,  MD, FRCPC, Professor, University of Calgary Calgary, AB

Subcutaneous formulations in oncology have the potential to provide comparable efficacy, PK & safety demonstrated by IV formulations and offer  convenience for patients and oncology health care professionals. This symposium will help oncology pharmacists to better understand the science of developing subcutaneous formulations, the current evidence in hematology and breast cancer and the potential impact on cancer centers. 

Learning Objectives:
  1. Recognize the complexities of developing subcutaneous formulations for use in oncology;
  2. Review the evidence supporting the use of subcutaneous formulations in hematology and breast oncology; and
  3. Assess the impact of introducing subcutaneous formulations within cancer centers.

Saturday, May 5

Satellite Symposium - BD Canada (07:00 - 08:30)

Panel discussion: Implementing Effective Strategies to Manage New Drug Waste Costs When Complying With the Beyond Use Dating Requirements of the NAPRA Model Standards.

Rick Abbott, Eastern Health, St. John's, NL
Lindsey Amerine, University of North Carolina (UNC) Medical Center, Chapel Hill, NC
Lily Spasic, Stronach Regional Cancer Centre, Newmarket, ON
Alicia Wall, Dr. H. Bliss Murphy Cancer Center and Health Sciences Center, St. John's, NL
Facilitator: Marshall Moleschi, Retired BC and Ontario Registrar, Toronto, ON

Based on the published NAPRA Model Standards for Hazardous Drug Compounding, it is anticipated that Canadian pharmacies will be required to discard single-dose drug vials 6 hours following first puncture. This is a change in practice that will have a significant impact on budgets, increasing the costs of drug wastage. Therefore finding strategies to manage these new drug waste costs is key to many Canadian pharmacies. This symposium will provide a review of these requirements, and how two institutions have achieved significant savings by using Closed System Transfer Devices to prevent microbial ingress and extend the life of the vial.

Learning Objectives:
  • A review of the new NAPRA Beyond Use Dating requirements for single-dose vials;
  • A review of a large US institution’s approach to optimizing single dose vials;
  • A Canadian approach to optimizing single dose vials and preventing waste; and
  • A practical approach to initiating sterility testing.  

Sunday, May 6

Satellite Symposium - Janssen (07:00 - 08:30)

CLL Management in the Era of Novel Therapies

Isabelle Bence-Bruckler, The Ottawa Hospital, Ottawa, ON
Ali Thawer, Odette Cancer Center Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON

Chronic Lymphocytic Leukemia (CLL) is a type of blood cancer that results in an oversupply of immature lymphocytes causing increased risk for infection, anemia, and blood clotting disorders. CLL has traditionally been treated with IV-delivered drugs. More recently novel oral compounds have been approved heightening the need for increased surveillance by pharmacists of potential drug-drug interactions. Furthermore, CLL predominately affects older individuals who are more likely to have been prescribed medications for other comorbidities. A multidisciplinary panel will present the evidence of CLL treatment options including data on drug-drug interactions and how this information may impact pharmacist patient management. 

Satellite Symposium - Purdue (12:30 - 14:00)

Chemotherapy Induced Nausea and Vomiting (CINV): Incorporating Patient Risk Factors into Clinical Practice

George Dranitsaris, B.Pharm, MS, PhD, FCSHP, Toronto, ON

Despite important advances in new and effective preventative antiemetics, CINV remains among the most unpleasant and feared side effect of cancer chemotherapy. Evidence-based antiemetic guidelines have been developed by the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the Multinational Association of Supportive Care in Cancer (MASCC). These guidelines have been instrumental in communicating the emetogenicity of various anticancer drugs, but do not currently consider patient factors that may increase a patient’s risk of CINV. Some of these factors include patient age, history of morning sickness, anxiety before chemotherapy and anticipatory N&V.  In this session, the various patient risk factors for CINV will be reviewed.  A systematic method to quantify and apply these risk factors towards personalized antiemetic care will then be presented.

Learning Objectives:
  • To recognize individual patient risk factors that may increase the risk of CINV;
  • To identify and quantify which patients are at “high risk” for CINV; and
  • To develop a systematic process for personalized antiemetic care.